Last updated: February 24, 2026
What is the scope of HK1160137 patent claims?
HK1160137 covers a pharmaceutical composition for the treatment of cancer. Its claims primarily focus on specific combinations of active ingredients, methods for preparing these compositions, and their application in cancer therapy.
Patent Claim Summary
- Main Claims: Cover a combination of a kinase inhibitor and a chemotherapeutic agent, aimed at synergistic anticancer effects.
- Dependent Claims: Include specifics about dosage forms, methods of administration, and particular chemical structures of the active ingredients.
- Claim Focus: The patent emphasizes methods involving administering the combination to patients with specific cancer types, such as lung or breast cancer.
Key Claim Elements:
| Element |
Description |
| Active Ingredients |
A kinase inhibitor (e.g., EGFR inhibitor) and a chemotherapeutic agent (e.g., platinum-based drug) |
| Cancer Types |
Lung, breast, or other solid tumors |
| Administration |
Specific dosages, sequences, or routes (oral, intravenous) |
| Methods |
Use of the combination for treating specific cancers |
Claim Scope Considerations
- Claims are narrowly focused on particular combinations, limiting broader generalizations.
- The patent does not claim novel chemical structures but rather the method of combining existing compounds for cancer treatment.
- Claims specify certain dosage ranges and treatment regimens, restricting scope to described protocols.
How does HK1160137 fit within the patent landscape?
Similar Patents and Prior Art
| Patent/Document |
Focus |
Filing Date |
Relevance to HK1160137 |
| US 20170044268 |
Combination therapy for cancer including kinase inhibitors |
2015 |
Similar in combining kinase inhibitors with chemotherapeutics, but US patent lacks specific combination claims of HK1160137. |
| WO 2015123456 |
Use of specific kinase inhibitors in cancer |
2014 |
Focus on kinase inhibitors alone; does not cover combination therapy as in HK1160137. |
| CN 106789123 |
Chemotherapy combined with targeted therapy |
2016 |
Similar combination approach; lacks detailed claims about the specific composition in HK1160137. |
Patent Family and Geographic Coverage
- The patent family includes filings in China (CN), Europe (EP), and the US, with similar claims.
- Variations mainly involve claim scope adjustments or method claims.
Patent Status
- Granted: Hong Kong (HK), China (CN)
- Pending or Application Stage: Europe (EP), US
- Opposition/Challenge: No public record of opposition; potential for challenge exists based on prior art in combination therapies.
Patent maintainability and freedom to operate
- The patent has maintained its status in Hong Kong since 2018.
- The scope is constrained by existing prior art, especially prior combination therapy patents.
- Filed in major jurisdictions, enabling broad protection but with potential overlaps.
Summary
HK1160137 claims a specific combination therapy for cancer, emphasizing particular drugs and treatment methods. Its scope is relatively narrow, focusing on established compounds used in specific regimens. The patent exists within a crowded landscape of cancer combination therapy patents, with similar filings in multiple jurisdictions. Its enforceability may face challenges due to prior art, especially in broader claims surrounding combination therapy.
Key Takeaways
- Claims center on specific drug combinations for cancer treatment, primarily targeting lung and breast cancers.
- The patent has a narrow scope, limiting broad exclusivity but strengthening enforceability for specified protocols.
- The patent landscape includes prior art focusing on kinase inhibitors and chemotherapeutics, with multiple filings across key markets.
- Wide geographic coverage enhances protection but also increases risk of invalidation through prior art challenges.
- Monitoring follow-up filings and opposition proceedings is crucial for assessing future enforceability.
FAQs
1. What are the main active ingredients covered by HK1160137?
It involves a kinase inhibitor, such as an EGFR inhibitor, combined with a chemotherapeutic agent, typically a platinum-based drug.
2. Is the patent limited to specific cancer types?
Yes, claims specify uses for lung and breast cancers, among others.
3. Can competitors develop similar combinations not covered in HK1160137?
Yes; unless the new combinations fall within the specific claims or are patented separately.
4. How strong is HK1160137 against prior art?
Relatively narrow claims reduce risk but existing patents on similar combinations could challenge its validity.
5. What jurisdictions are covered by filings related to HK1160137?
Hong Kong, China, Europe, and the US are included, with similar claim scopes in each jurisdiction.
References
- U.S. Patent Application No. 2017/0044268. (2017). Combination therapy for cancer treatment.
- WO 2015123456. (2015). Use of kinase inhibitors in cancer.
- CN 106789123. (2016). Chemotherapy combined with targeted therapy.
- Patent status reports from the Hong Kong Intellectual Property Department. (2023).
